Sinopharm Group Co ( (HK:1099) ) has provided an update.
Sinopharm Group Co. Ltd. has announced the principal financial data for its subsidiary, China National Medical Device Co., Ltd. (CNMDC), for the year ended 31 December 2024. The report highlights a decline in revenue by 7.75% and a significant drop in operating profit by 53.02% compared to the previous year. Additionally, the total comprehensive income attributable to the parent company decreased by 60.88%, and net cash flow from operating activities turned negative. Despite these challenges, CNMDC’s total assets increased by 6.69%, indicating growth in its asset base, while total equity attributable to owners rose by 2.17%. These financial results may impact the company’s market positioning and stakeholder confidence.
More about Sinopharm Group Co
Sinopharm Group Co. Ltd. is a prominent company in the healthcare industry, focusing on the distribution and manufacturing of medical devices and pharmaceuticals. Its subsidiary, China National Medical Device Co., Ltd. (CNMDC), plays a significant role in the company’s operations, particularly in the medical device sector.
YTD Price Performance: -8.47%
Average Trading Volume: 1,250
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $7.95B
Find detailed analytics on 1099 stock on TipRanks’ Stock Analysis page.